IPSC
$2.29
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Intraday
Recent News
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission
Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company’s plan to submit an IND for CNTY-813 this year and deliver initial data by […]
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Promising Penny Stocks To Watch In January 2026
As of mid-January 2026, major U.S. stock indexes have been trending lower following a series of mixed bank earnings reports and economic data releases, while gold and silver have reached record highs. In this context, investors often look to less conventional areas of the market for potential opportunities. Penny stocks, though considered a somewhat outdated term, still represent an intriguing investment area due to their potential for growth at lower price points. These smaller or newer...
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug
Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.